The DOI matches its Crossref record; 206 of the 206 references it cites were found in a registry or an index.
The non‐haematopoietic biological effects of erythropoietin
Open accessAbstract
Summary: In the haematopoietic system, the principal function of erythropoietin (Epo) is the regulation of red blood cell production, mediated by its specific cell surface receptor (EpoR). Following the cloning of the Epo gene (EPO) and characterization of the selective haematopoietic action of Epo in erythroid lineage cells, recombinant Epo forms (epoetin‐alfa, epoetin‐beta and the long‐acting analogue darbepoetin‐alfa) have been widely used for treatment of anaemia in chronic kidney disease and chemotherapy‐induced anaemia in cancer patients. Ubiquitous EpoR expression in non‐erythroid cells has been associated with the discovery of diverse biological functions for Epo in non‐haematopoietic tissues. During development, Epo–EpoR signalling is required not only for fetal liver erythropoiesis, but also for embryonic angiogenesis and brain development. A series of recent studies suggest that endogenous Epo–EpoR signalling contributes to wound healing responses, physiological and pathological angiogenesis, and the body’s innate response to injury in the brain and heart. Epo and its novel derivatives have emerged as major tissue‐protective cytokines that are being investigated in the first human studies involving neurological and cardiovascular diseases. This review focuses on the scientific evidence documenting the biological effects of Epo in non‐haematopoietic tissues and discusses potential future applications of Epo and its derivatives in the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Erythropoietin was originally recognized via its role in erythropoiesis [2145-2147] (hence its name, of course), but it has become evident that it has many other roles, and in particular it is observed phenomenologically that erythropoietin (and non-erthyropoetic derivatives) is protective in a number of inflammatory conditions that accompany many diseases such as those listed above [940,942,2148-”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Galeano, M., Altavilla, D., Bitto, A., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000206468.18653.ec · Cited by 151
RetractedCorrection of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762
Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
Drüeke, T. B., Locatelli, F., Clyne, N., Eckardt, K., Macdougall, I. C., Tsakiris, D., Burger, H.-U., & Scherhag, A. W. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062276 · Cited by 2,094
Besarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390903 · Cited by 1,930
Yöder, M. C., Mead, L. E., Prater, D. N., Krier, T. R., Mroueh, K. N., Li, F., Krasich, R., Temm, C. J., Prchal, J. T., & Ingram, D. A. (2006) · Blood · doi:10.1182/blood-2006-08-043471 · Cited by 1,486
Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury
Brines, M. L., Ghezzi, P., Keenan, S., Agnello, D., de Lanerolle, N. C., Cerami, C., Itri, L. M., & Cerami, A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.19.10526 · Cited by 1,402
Henke, M., Laszig, R., Rübe, C., Schäfer, U., Haase, K.-D., Schilcher, B., Mose, S., Beer, K. T., Burger, U., Dougherty, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14567-9 · Cited by 1,248
Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress
Sirén, A., Fratelli, M., Brines, M. L., Goemans, C. G., Casagrande, S., Lewczuk, P., Keenan, S., Gleiter, C. H., Pasquali, C., Capobianco, A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051606598 · Cited by 1,019
Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial
Ehrenreich, H., Hasselblatt, M., Dembowski, C., Cepek, L., Lewczuk, P., Stiefel, M., Rustenbeck, H.-H., Breiter, N., Jacob, S., Knerlich‐Lukoschus, F., et al. (2002) · Molecular Medicine · doi:10.1007/bf03402029 · Cited by 1,017
Wu, H., Liu, X., Jaenisch, R., & Lodish, H. F. (1995) · Cell · doi:10.1016/0092-8674(95)90234-1 · Cited by 1,007
Research works printed but not linked: 1
- 10.1182/blood.V92.9.3218 · DOI
Cited by
Sorted by citations
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
Silverberg, D. S. (2011) · Heart Failure Reviews · doi:10.1007/s10741-010-9194-2 · Cited by 48
Metadata
- Authors
- Arcasoy, M. O.
- Affiliations
- Duke Medical Center (US)
- Corresponding author
- Arcasoy, Murat O.
- ORCID
- Arcasoy, Murat O.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2008-03-06
- Volume
- 141
- Issue
- 1
- Pages
- 14-31
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2088369648
- Cited by
- 347
- References
- 206
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 6 · 2023: 5 · 2022: 8 · 2021: 9 · 2020: 11 · 2019: 12 · 2018: 15 · 2017: 15 · 2016: 12 · 2015: 12 · 2014: 18 · 2013: 38 · 2012: 28
- FWCI
- 6.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- British Journal of Haematology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense
- American Heart Association
- National Institutes of Health (5r21dk065065-02)
- National Cancer Institute (CA100844, R01CA100844)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK65065)
- Topics
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
- Keywords
- erythropoietin, erythropoietin receptor, epoetin alfa, epoetin beta, darbepoetin alfa, angiogenesis, wound healing, brain development, embryonic development, tissue protection, anemia of chronic kidney disease, chemotherapy-induced anemia, neuroprotection, cardioprotection
- MeSH terms
- Animals, Cardiotonic Agents, Cardiovascular Physiological Phenomena, Erythropoietin, Humans, Nervous System Physiological Phenomena, Recombinant Proteins, Wound Healing, Signal Transduction, Receptors, Erythropoietin, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
